Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates: preclinical review.

Jonathan R Green1

  • 1Novartis Pharma AG, Klybeckstrasse 141, WKL-125.901, CH-4002 Basel, Switzerland. jonathan.green@pharma.novartis.com

The Oncologist
|October 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods for tagging whale sharks: insights into performance and best practices with a focus on clamp attachments.

Animal biotelemetry·2026
Same author

Climate-driven global redistribution of an ocean giant predicts increased threat from shipping.

Nature climate change·2024
Same author

Identifying priority sites for whale shark ship collision management globally.

The Science of the total environment·2024
Same author

Species associated with whale sharks <i>Rhincodontypus</i> (Orectolobiformes, Rhincodontidae) in the Galapagos Archipelago.

Biodiversity data journal·2024
Same author

Diving into the vertical dimension of elasmobranch movement ecology.

Science advances·2022
Same author

Global collision-risk hotspots of marine traffic and the world's largest fish, the whale shark.

Proceedings of the National Academy of Sciences of the United States of America·2022
Same journal

Durable Response to Sotorasib in KRAS G12C-Mutant Intrahepatic Cholangiocarcinoma: A Case Report.

The oncologist·2026
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
See all related articles

Nitrogen-containing bisphosphonates (N-BPs) target osteoclasts and tumor cells by inhibiting the mevalonate pathway, inducing apoptosis, and potentially offering antitumor effects. Further clinical studies are needed to confirm their therapeutic potential in cancer treatment.

Area of Science:

  • Pharmacology and Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Bisphosphonates are crucial for treating bone diseases by inhibiting osteoclast activity.
  • Nitrogen-containing bisphosphonates (N-BPs) represent an evolution with distinct mechanisms compared to non-nitrogenous bisphosphonates.
  • Recent research has clarified the mechanisms and properties of N-BPs.

Purpose of the Study:

  • To elucidate the mechanism of action and pharmacologic properties of N-BPs.
  • To explore the antitumor effects of N-BPs, including their impact on protein prenylation and apoptosis.
  • To investigate the potential of zoledronic acid as an anticancer agent, alone and in combination therapy.

Main Methods:

  • Investigated the inhibition of farnesyl diphosphate synthase in the mevalonate pathway by N-BPs.

Related Experiment Videos

  • Examined the induction of apoptosis via adenosine triphosphate analogue (Apppi) production.
  • Assessed the effects of N-BPs on protein prenylation, caspase activation, matrix metalloproteinase activity, and integrin expression.

    • Main Results:

    • N-BPs inhibit osteoclasts and tumor cells by blocking protein prenylation, a key step in intracellular signaling.
    • N-BPs induce caspase-dependent apoptosis and inhibit matrix metalloproteinase activity and integrin expression.
    • Zoledronic acid demonstrates synergistic antitumor activity, inhibits tumor cell adhesion and invasion, and possesses antiangiogenic properties.

    Conclusions:

    • N-BPs exert antitumor effects through biochemical mechanisms including apoptosis induction and inhibition of key cellular processes.
    • Zoledronic acid shows promise in preclinical models for reducing skeletal tumor burden and preventing bone metastasis.
    • Further research is essential to fully understand these mechanisms and translate the antitumor potential of bisphosphonates into clinical applications.